Advisory Board

Prof. Oren is a renowned specialist in gastroenterology and liver diseases, heading the Institute of Gastroenterology and Liver Diseases at Hadassah Hospital in Jerusalem, Israel. Prof. Oren is the former director of the Division of Internal Medicine at the Tel-Aviv Sourasky Medical Center in Tel Aviv, Israel. Prof. Oren has also served as Chair for the Israeli Society for Liver Diseases between 2007-2010.

Prof. Barenholz is a renowned specialist in biochemistry, biophysics, nanotechnology and cancer, with 46 years of experience in research and development. Prof. Barenholz is the head of the Laboratory of Membrane and Liposome Research at the Department of Biochemistry, the Hebrew University–Hadassah Medical School, Jerusalem, Israel. Prof. Barenholz is the author of over 350 publications and the editor of academic journals and books. He is the co-inventor of over 30 patent families, two of which underlie Doxil® for the treatment of breast and ovarian cancer. Doxil® is the first liposomal drug and the first nano-medicine that was approved by the FDA.

Prof. Borody is the founder and manager of the Centre for Digestive Diseases in Sydney, Australia. Prof. Borody has vast experience in drug development projects as an inventor and investigator. Prof. Borody is considered to be the first physician to successfully formulate the triple therapy that would later become the gold standard for treating peptic ulcer disease caused by Helicobacter pylori infection. The triple therapy was invented in 1984 together with Dr. Barry Marshal and Dr. Robin Warren (who later received a Nobel prize for their research into Helicobacter pylori). Prof. Borody is the inventor of RedHill’s RHB-104 for the treatment of MAP in Crohn’s.

Dr. Rosenblatt is a Partner at Foster Rosenblatt, an international market research and advisory firm, exclusively focused on life sciences. Dr. Rosenblatt is a former Professor of Marketing, Associate Dean and Director of the MBA and Executive Development Programs at the John Molson School of Business, Concordia University, Montreal. He is a former Professor of Marketing and graduate of McGill University, one of Canada’s leading academic institutions. Dr. Rosenblatt was the Global Practice Leader, Forecasting and Opportunity Assessment practice for IMS Consulting (a leading healthcare research company), with over 25 years of experience as marketing advisor to pharmaceutical companies.

Prior to joining RedHill, Dr. Kalfus served as VP of Medical Affairs at Lev Pharmaceuticals. He was previously with Aetna/U.S. Healthcare, Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). Dr. Kalfus completed his residency in Internal Medicine at LIJ and is a graduate of the Albert Einstein College of Medicine (M.D.) and Columbia University (B.A. in Biology). Dr. Kalfus led the successful Phase 3 RHB-105 (Talicia) program whose NDA was filed in May 2019, as well as the positive Phase 3 program in Crohn’s disease while serving as Medical Director at RedHill. He is currently Chief Medical Officer of Attune Pharmaceuticals as well as Chief Medical Officer of LifeSci Venture Partners.

Dr. Tschollar, based in Switzerland, is a former Senior Vice President, Worldwide R&D at Novartis Consumer Pharmaceuticals. Dr. Tschollar led and held senior executive positions in several biopharmaceutical companies including, among others, Bristol-Myers Squibb/Princeton, Schering-Plough, Xytis, Inc. and Neurim Pharmaceuticals Ltd.

Dr. Scott Harris is Chief Medical Officer of Altimmune (NASDAQ: ALT) and Principal of Middleburg Consultants, a consulting firm specializing in pharmaceutical development in gastrointestinal diseases. He has led numerous GI studies and programs in the U.S. and rest-of world. Dr. Harris is also Co-Founder and Chief Medical Officer of Lyric Pharmaceuticals and previously served as Chief Medical Officer of Avaxia Biologics, interim Chief Medical Officer of Tranzyme Pharmaceuticals, Chief Medical Officer of Ocera Therapeutics and Chief Medical Officer and Vice President of Clinical Affairs at Napo Pharmaceuticals. He is currently Adjunct Professor of Medicine at Georgetown University School in Washington, DC. Dr. Harris has been a consultant on third-world drug development for the Bill and Melinda Gates Foundation and PATH and a speaker at national and international forums on gastrointestinal drug development.

Prof. Sir Colin Blakemore FRS, FMedSci, HonFRCP, HonFRSM, HonFRSB, HonFBPhS, MAE, Emeritus Professor of Physiology, University of Oxford, Emeritus Fellow of Magdalen College, Oxford and RedHill’s Advisory Board member and dear friend passed away in June 2022.

Prof. Blakemore was a world-renowned neuroscientist that made profound contributions to our understanding of vision and brain development and was well known for his public engagement and service.

Prof. Blakemore held a number of prominent positions throughout his lifetime. He was a Waynflete Professor of Physiology at the University of Oxford, the youngest to be appointed to the position at the age of 35. He served as chief executive of the British Medical Research Council, where he instituted impactful reforms. He served as president of the Biosciences Federation (now known as the Society of Biology) and more, held chairs at academic institutions around the world, and served as an advisor to organizations, including government departments, agencies and foundations dedicated to science. Prof. Blakemore received numerous academic honors throughout his lifetime for his scientific contributions, including the knighthood in 2014 for his “services to scientific research, policy, and outreach”.

Prof. Blakemore was regarded as “a passionate advocate for physiology”. He was known to publicly address and encourage debate about controversial and challenging issues for the advancement of science. Despite fierce and sometimes life-threatening opposition, Prof. Blakemore was an outspoken supporter of the use of responsible animal testing in biomedical research.

Prof. Blakemore leaves a remarkable legacy of scientific contributions behind him. Regarded as “passionate” and “profoundly influential”, Prof. Blakemore has impacted and inspired the lives of many through his scientific research and teachings. We are proud and thankful for his ongoing contribution throughout the years to the RedHill family. He will be missed by many.

Mr. Schwartz based in Toronto, is the founder and president of Schwartz Technologies Corporation and acts as an advisor to Covalon Technologies. Mr. Schwartz founded and held executive positions in various companies, including, among others, President and CEO of Cedara Software Corp. Mr. Schwartz has over 35 years of experience in launching products, R&D, international distribution agreements, re-organization in large scale corporations, financing and M&A.

Dr. Joshua Schein, a valued member of RedHill's Advisory Board, passed away in June 2019. He will be greatly missed.